Bovalto Ibraxion
Infectious bovine rhinotracheitis vaccine (inactivated)
Table of contents
Overview
The marketing authorisation for Bovalto Ibraxion has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Bovalto Ibraxion
|
| Agency product number |
EMEA/V/C/000051
|
| Active substance |
inactivated IBR virus
|
| International non-proprietary name (INN) or common name |
Infectious bovine rhinotracheitis vaccine (inactivated)
|
| Species |
Cattle
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI02AA03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Merial
|
| Revision |
10
|
| Date of issue of marketing authorisation valid throughout the European Union |
09/03/2000
|
| Contact address |
29 Avenue Tony Garnier |
Product information
10/08/2016 Bovalto Ibraxion - EMEA/V/C/000051 - IAIN/0016
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.
The onset of immunity is 14 days and the duration of immunity is 6 months.